{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:01:56Z","timestamp":1715965316528},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen. He underwent esophagogastroduodenoscopy in September 2009, which revealed a 2-cm gastric ulcer on the lesser curvature proximal to angularis. Biopsy of gastric ulcer showed moderately differentiated adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry and fluorescence in situ hybridization. Further workups with endoscopic ultrasound, computed tomography and positron emission tomography staged his cancer as T3N1M0. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, docetaxel and capecitabine without severe toxicities except grade 2 diarrhea near the completion of cycle 3 requiring discontinuation of capecitabine. Afterwards, he received total gastrectomy with extended D2 lymph node dissections showing pathological complete response. He went on to receive 3 more cycles of chemotherapy postoperatively. The role of trastuzumab as a part of perioperative therapy in gastric cancer overexpressing HER2 is worth further investigation.<\/jats:p>","DOI":"10.1186\/1756-8722-3-31","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T18:14:44Z","timestamp":1284056084000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report"],"prefix":"10.1186","volume":"3","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W","family":"Saukel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A","family":"Garberoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichit","family":"Srikureja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Tsen","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,9]]},"reference":[{"issue":"14","key":"115_CR1","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF: Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. J Clin Oncol. 2006, 24 (14): 2137-2150. 10.1200\/JCO.2005.05.2308.","journal-title":"J Clin Oncol"},{"issue":"1","key":"115_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ: Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006, 355 (1): 11-20. 10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"issue":"3","key":"115_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00000658-199903000-00001","volume":"229","author":"AM Lowy","year":"1999","unstructured":"Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA: Response to Neoadjuvant Chemotherapy Best Predicts Survival After Curative Resection of Gastric Cancer. Annals of Surgery. 1999, 229 (3): 303-308. 10.1097\/00000658-199903000-00001.","journal-title":"Annals of Surgery"},{"issue":"24","key":"115_CR4","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","volume":"24","author":"JA Ajani","year":"2006","unstructured":"Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006, 24 (24): 3953-3958. 10.1200\/JCO.2006.06.4840.","journal-title":"J Clin Oncol"},{"issue":"7","key":"115_CR5","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1078-0432.CCR-07-0934","volume":"14","author":"K Ott","year":"2008","unstructured":"Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K: Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. Clinical Cancer Research. 2008, 14 (7): 2012-2018. 10.1158\/1078-0432.CCR-07-0934.","journal-title":"Clinical Cancer Research"},{"key":"115_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-3-11","volume":"3","author":"M Javle","year":"2010","unstructured":"Javle M, Hsueh CT: Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol. 2010, 3: 11-10.1186\/1756-8722-3-11.","journal-title":"J Hematol Oncol"},{"issue":"4730","key":"115_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.2999974","volume":"230","author":"L Coussens","year":"1985","unstructured":"Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230 (4730): 1132-1139. 10.1126\/science.2999974.","journal-title":"Science"},{"issue":"8","key":"115_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10620-005-9057-1","volume":"51","author":"D Park","year":"2006","unstructured":"Park D, Yun J, Park J, Oh S, Kim H, Cho Y, Sohn C, Jeon W, Kim B, Yoo C: HER-2\/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences. 2006, 51 (8): 1371-1379. 10.1007\/s10620-005-9057-1.","journal-title":"Digestive Diseases and Sciences"},{"issue":"1","key":"115_CR9","first-page":"89","volume":"32","author":"SY Kim","year":"2008","unstructured":"Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, Jong HS, Kim TY, Bang YJ: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008, 32 (1): 89-95.","journal-title":"Int J Oncol"},{"issue":"2","key":"115_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005, 16 (2): 273-278. 10.1093\/annonc\/mdi064.","journal-title":"Ann Oncol"},{"issue":"6","key":"115_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00280-006-0337-z","volume":"59","author":"K Fujimoto-Ouchi","year":"2007","unstructured":"Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology. 2007, 59 (6): 795-805. 10.1007\/s00280-006-0337-z.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"18_suppl","key":"115_CR12","doi-asserted-by":"crossref","first-page":"4613-","DOI":"10.1200\/jco.2007.25.18_suppl.4613","volume":"25","author":"H Cortes-Funes","year":"2007","unstructured":"Cortes-Funes H, Rivera F, Ales I, Marquez A, Velasco A, Colomer R, Garcia-Carbonero R, Sastre J, Guerra J, Gravalos C: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2\/neu overexpression\/amplification. J Clin Oncol (Meeting Abstracts). 2007, 25 (18_suppl): 4613--","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"9","key":"115_CR13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008, 19 (9): 1523-1529. 10.1093\/annonc\/mdn169.","journal-title":"Ann Oncol"},{"issue":"15S","key":"115_CR14","doi-asserted-by":"crossref","first-page":"LBA4509-","DOI":"10.1200\/jco.2009.27.15_suppl.lba4509","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol (Meeting Abstracts). 2009, 27 (15S): LBA4509--","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"15S","key":"115_CR15","doi-asserted-by":"crossref","first-page":"4556-","DOI":"10.1200\/jco.2009.27.15_suppl.4556","volume":"27","author":"Y Bang","year":"2009","unstructured":"Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J, Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol (Meeting Abstracts). 2009, 27 (15S): 4556--","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"1","key":"115_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med. 2008, 358 (1): 36-46. 10.1056\/NEJMoa073149.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"115_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1634\/theoncologist.10-90003-49","volume":"10","author":"JA Ajani","year":"2005","unstructured":"Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005, 10 (Suppl 3): 49-58. 10.1634\/theoncologist.10-90003-49.","journal-title":"Oncologist"},{"issue":"31","key":"115_CR18","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006, 24 (31): 4991-4997. 10.1200\/JCO.2006.06.8429.","journal-title":"J Clin Oncol"},{"key":"115_CR19","volume-title":"Acta Oncol","author":"M Andersen","year":"2010","unstructured":"Andersen M, Schonnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P: Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncol. 2010,"},{"issue":"15S","key":"115_CR20","doi-asserted-by":"crossref","first-page":"4554-","DOI":"10.1200\/jco.2009.27.15_suppl.4554","volume":"27","author":"MH Moehler","year":"2009","unstructured":"Moehler MH, Thuss-Patience P, Arnold D, Grothe W, Stein A, Seufferlein T, Mantovani Loeffler L, Geissler M, Hofheinz RD, Schmoll H: Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group. J Clin Oncol (Meeting Abstracts). 2009, 27 (15S): 4554--","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"8","key":"115_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMp058315","volume":"354","author":"KR Chien","year":"2006","unstructured":"Chien KR: Herceptin and the Heart -- A Molecular Modifier of Cardiac Failure. N Engl J Med. 2006, 354 (8): 789-790. 10.1056\/NEJMp058315.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-3-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:37:56Z","timestamp":1630471076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-3-31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-3-31","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,9]]},"assertion":[{"value":"30 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"31"}}